- Home
- / Asterias Biotherapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Asterias Biotherapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$4 M
FY, 2017
CreditSafe Score
?
Score changed on Jul 24, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|
| Revenue | 1.2M | 3.6M | 7.0M | 4.0M | |
| Revenue growth, % | 94.1% | ||||
| Cost of goods sold | 94.6K | 268.0K | 128.0K | 165.0K | |
| Gross profit | 1.1M | 3.3M | 6.8M | 3.9M | |
| Gross profit margin, % | 92.3% | 92.5% | 98.2% | 95.9% | |
| Operating expense total | 18.6M | 25.2M | 40.9M | 37.1M | |
| EBIT | (25.7M) | (17.5M) | (21.9M) | (34.1M) | (33.3M) |
| EBIT margin, % | -1427.0% | -611.6% | -490.7% | -822.6% | |
| Interest income | 1.0K | 1.6K | |||
| Interest expense | 1.0K | 10.0K | 341.0K | 546.0K | 465.0K |
| Pre tax profit | (25.7M) | (17.5M) | (22.3M) | (37.8M) | (28.4M) |
| Income tax expense | (3.3M) | (7.4M) | (7.3M) | (2.3M) | |
| Net Income | (22.4M) | (10.1M) | (15.0M) | (35.5M) | (28.4M) |